Advertisement

Systolic Hypertension in the Elderly: Addressing an Unmet Need

  • Daniel A. Duprez
    Correspondence
    Requests for reprints should be addressed to Daniel A. Duprez, MD, PhD, Department of Medicine, Cardiovascular Division, VCRC - Room 270, University of Minnesota, 420 Delaware St. SE, MMC 508, Minneapolis, MN 55455.
    Affiliations
    Cardiovascular Division, Medical School, University of Minnesota, Minn.
    Search for articles by this author

      Abstract

      Systolic hypertension is a major public health issue in the elderly and is often under-recognized and under-treated. The concept that systolic blood pressure increases with age should be considered a pathophysiologic concept. Aging of the cardiovascular system is accompanied by endothelial dysfunction, activation of the renin-angiotensin system and, consequently, vascular remodeling. This process leads to an increase in large artery stiffness and an increase in arterial wave reflections to the heart. These processes in daily clinical practice translate to an increase in systolic blood pressure, which is associated with increased cardiovascular morbidity and mortality. Evidence-based medicine recommendations to treat systolic hypertension in the elderly are based on landmark and recent clinical trials, which clearly demonstrated that treatment of isolated systolic hypertension is associated with significant decreases in cardiovascular morbidity and mortality. However, treatment of systolic hypertension in older adults remains disappointing because therapeutic goals often are not reached. Therefore, emphasis should be placed on the treatment of systolic hypertension in the elderly, and there is need for more effective, individualized antihypertensive therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Franklin S.S.
        • Jacobs M.J.
        • Wong N.D.
        • et al.
        Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.
        Hypertension. 2001; 37: 869-874
        • Hajjar I.
        • Kotchen T.A.
        Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.
        JAMA. 2003; 290: 199-206
        • Fields L.E.
        • Burt V.L.
        • Cutler J.A.
        • et al.
        The burden of adult hypertension in the United States 1999 to 2000: a rising tide.
        Hypertension. 2004; 44: 398-404
        • Crimmins E.M.
        • Alley D.
        • Reynolds S.L.
        • et al.
        Changes in biological markers of health: older Americans in the 1990s.
        J Gerontol A Biol Sci Med Sci. 2005; 60: 1409-1413
        • Pepe S.
        • Lakatta E.G.
        Aging hearts and vessels: masters of adaptation and survival.
        Cardiovasc Res. 2005; 66: 190-193
        • O’Rourke M.F.
        • Safar M.E.
        Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy.
        Hypertension. 2005; 46: 200-204
        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • et al.
        Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • Duprez D.A.
        Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
        J Hypertens. 2006; 24: 983-991
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Devereux R.B.
        • Palmieri V.
        • Sharpe N.
        • et al.
        Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial.
        Circulation. 2001; 104: 1248-1254
        • Jafar T.H.
        • Schmid C.H.
        • Landa M.
        • et al.
        Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data.
        Ann Intern Med. 2001; 135: 73-87
        • Vogt L.
        • Navis G.
        • Koster J.
        • et al.
        The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
        J Hypertens. 2005; 23: 2055-2061
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • SHEP Cooperative Research Group
        Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
        JAMA. 1991; 265: 3255-3264
        • Kostis J.B.
        • Wilson A.C.
        • Freudenberger R.S.
        • et al.
        Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
        Am J Cardiol. 2005; 95: 29-35
        • Sutton-Tyrrell K.
        • Wildman R.
        • Newman A.
        • Kuller L.H.
        Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension.
        Arch Intern Med. 2003; 163: 2728-2731
        • Staessen J.A.
        • Fagard R.
        • Thijs L.
        • et al.
        Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.
        Lancet. 1997; 350: 757-764
        • Liu L.
        • Wang J.G.
        • Gong L.
        • et al.
        • Systolic Hypertension in China (Syst-China) Collaborative Group
        Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension.
        J Hypertens. 1998; 16: 1823-1829
        • Staessen J.A.
        • Gasowski J.
        • Wang J.G.
        • et al.
        Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.
        Lancet. 2000; 355: 865-872
        • Kjeldsen S.E.
        • Dahlof B.
        • Devereux R.B.
        • et al.
        Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
        JAMA. 2002; 288: 1491-1498
        • Lithell H.
        • Hansson L.
        • Skoog I.
        • et al.
        The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
        J Hypertens. 2003; 21: 875-886
        • Malacco E.
        • Mancia G.
        • Rappelli A.
        • et al.
        Treatment of isolated systolic hypertension: the SHELL study results.
        Blood Press. 2003; 12: 160-167
        • Mancia G.
        • Ruilope L.M.
        • Palmer C.R.
        • et al.
        Effects of nifedipine GITS and diuretics in isolated systolic hypertension—a subanalysis of the INSIGHT study.
        Blood Press. 2004; 13: 310-315
        • Malacco E.
        • Vari N.
        • Capuano V.
        • et al.
        A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
        Clin Ther. 2003; 25: 2765-2780
        • London G.
        • Schmieder R.
        • Calvo C.
        • Asmar R.
        Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
        Am J Hypertens. 2006; 19: 113-121
        • Duprez D.A.
        • Cohn J.N.
        Monitoring vascular health beyond blood pressure.
        Curr Hypertens Rep. 2006; 8: 287-291
        • Duprez D.A.
        • Somasundaram P.E.
        • Sigurdsson G.
        • et al.
        Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.
        J Hum Hypertens. 2005; 19: 515-519
        • Williams B.
        • Lacy P.S.
        • Thom S.M.
        • et al.
        Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
        Circulation. 2006; 113: 1213-1225
        • Azizi M.
        • Webb R.
        • Nussberger J.
        • Hollenberg N.K.
        Renin inhibition with aliskiren: where are we now, and where are we going?.
        J Hypertens. 2006; 24: 243-256
        • Stanton A.
        • Jensen C.
        • Nussberger J.
        • O’Brien E.
        Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
        Hypertension. 2003; 42: 1137-1143
        • Oh B.-H.
        • Mitchell J.
        • Herron J.R.
        • et al.
        Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
        J Am Coll Cardiol. 2007; 49: 1157-1163
        • Oparil S.
        • Yarows S.A.
        • Patel S.
        • et al.
        Antihypertensive efficacy and safety of dual renin system intervention with aliskiren, an oral direct renin inhibitor, and valsartan: a randomized, double-blind comparison versus monotherapy.
        Lancet. 2007; 370: 221-229